| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8f071a0602525a55a1c409029e73b439 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F5-022 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-14 |
| filingDate |
2019-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2bb9c4c8ffa6cc8a4112043694f970c1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_43a0318bf0cbf0700812a30e001dbd41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf4db0288d6d9f82e45eb3da3cba82e8 |
| publicationDate |
2020-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10752642-B1 |
| titleOfInvention |
Macrocyclic lactones |
| abstract |
The present compositions and methods generally relate to the treatment of diseases, such as idiopathic pulmonary fibrosis (IPF) and neurodegenerative diseases related to tau aggregation. In particular, the compositions relate to compounds or pharmaceutically acceptable salts of Formula I: |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11666560-B2 |
| priorityDate |
2019-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |